MX2009004223A - Immunization protocol against the 4 dengue serotypes. - Google Patents

Immunization protocol against the 4 dengue serotypes.

Info

Publication number
MX2009004223A
MX2009004223A MX2009004223A MX2009004223A MX2009004223A MX 2009004223 A MX2009004223 A MX 2009004223A MX 2009004223 A MX2009004223 A MX 2009004223A MX 2009004223 A MX2009004223 A MX 2009004223A MX 2009004223 A MX2009004223 A MX 2009004223A
Authority
MX
Mexico
Prior art keywords
administration
immunization protocol
dengue
dengue serotypes
vaccine
Prior art date
Application number
MX2009004223A
Other languages
Spanish (es)
Inventor
Bruno Guy
Veronique Barban
Remi Forrat
Jean Lang
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Publication of MX2009004223A publication Critical patent/MX2009004223A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention relates to a method to induce a protection against the 4 dengue serotypes in a patient, comprising: (a) the administration of a monovalent vaccine comprising a vaccine virus of a first dengue serotype, and (b) the administration of a tetravalent vaccine comprising vaccine viruses of the four serotypes of dengue, wherein the administration (b) is implemented at least 30 days to at most 12 months after the first administration (a).
MX2009004223A 2006-12-01 2007-11-30 Immunization protocol against the 4 dengue serotypes. MX2009004223A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0655255A FR2909286B1 (en) 2006-12-01 2006-12-01 IMMUNIZATION METHOD AGAINST THE 4 SEROTYPES OF DENGUE
PCT/FR2007/052431 WO2008065315A1 (en) 2006-12-01 2007-11-30 Immunization protocol against the 4 dengue serotypes

Publications (1)

Publication Number Publication Date
MX2009004223A true MX2009004223A (en) 2009-04-30

Family

ID=38198298

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004223A MX2009004223A (en) 2006-12-01 2007-11-30 Immunization protocol against the 4 dengue serotypes.

Country Status (16)

Country Link
US (2) US7718359B2 (en)
EP (1) EP2099483B1 (en)
JP (1) JP5269803B2 (en)
KR (1) KR20090087890A (en)
CN (1) CN101541344A (en)
AR (1) AR064009A1 (en)
AU (1) AU2007327367B2 (en)
BR (1) BRPI0718927A2 (en)
CA (1) CA2668570A1 (en)
FR (1) FR2909286B1 (en)
IL (2) IL198466A (en)
MX (1) MX2009004223A (en)
MY (1) MY180698A (en)
TW (1) TWI400249B (en)
WO (1) WO2008065315A1 (en)
ZA (1) ZA200902540B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006280144B2 (en) * 2005-08-10 2012-06-14 Sanofi Pasteur Biologics, Llc Vaccination against dengue virus infection
FR2903605A1 (en) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa IMMUNIZATION METHOD AGAINST THE FOUR SEROTYPES OF DENGUE
FR2906724B1 (en) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa METHOD OF IMMUNIZATION AGAINST THE 4 SEROTYPES OF DENGUE.
BRPI0909820A2 (en) 2008-03-05 2015-08-11 Sanofi Pasteur Process for stabilizing influenza vaccine composition, for stabilizing adjuvanted-containing vaccine composition and for preparing vaccine, vaccine compositions, vaccine kit and stockpiling method
EP2143440A1 (en) * 2008-07-09 2010-01-13 Sanofi Pasteur Stabilising agent and vaccine composition comprising one or several attenuated living flavivirus
NZ618158A (en) * 2009-06-01 2015-05-29 Takeda Vaccines Inc Compositions and methods for administration of vaccines against dengue virus
CA2770888C (en) * 2009-08-31 2020-04-14 Gen-Probe Incorporated Dengue virus assay
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
EP2654786B1 (en) 2010-12-20 2019-02-20 GenVec, Inc. Adenoviral vector-based dengue fever vaccine
WO2014016362A1 (en) 2012-07-24 2014-01-30 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
MY168959A (en) 2012-07-24 2019-01-28 Sanofi Pasteur Vaccine compositions for the prevention of dengue virus infection
BR112015012515B1 (en) 2012-11-30 2023-04-11 Sanofi Pasteur USE OF ANTIGENS, NUCLEIC ACID CONSTRUCTS OR VIRAL VECTORS CAPABLE OF EXPRESSING A VIRUS-LIKE PARTICLE (VLP) OF DENGUE AND A VACCINE AGAINST MEASLES, A VACCINE AGAINST MUMPS AND A VACCINE AGAINST RUBELLA
CN105246506A (en) * 2013-06-21 2016-01-13 默沙东公司 Dengue virus vaccine compositions and methods of use thereof
TW201620546A (en) 2014-09-02 2016-06-16 賽諾菲巴斯德公司 Vaccine compositions
BR112017028212A2 (en) 2015-07-03 2018-09-11 Sanofi Pasteur concomitant vaccination against dengue and yellow fever
US10004795B2 (en) * 2015-09-08 2018-06-26 Fundacao Butantan Process for preparing an attenuated tetravalent dengue vaccine
JP7313345B2 (en) 2017-10-05 2023-07-24 サノフィ・パスツール Composition for booster vaccination against dengue fever
IL298307A (en) 2018-09-05 2023-01-01 Takeda Vaccines Inc Dengue vaccine unit dose and administration thereof
CN114555113A (en) 2019-08-16 2022-05-27 武田疫苗股份有限公司 Method for preventing dengue fever and hepatitis A
US20240076631A2 (en) 2020-02-27 2024-03-07 Takeda Vaccines, Inc. Method for removing host cell dna from virus preparation
WO2023147342A2 (en) 2022-01-25 2023-08-03 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
WO2023158989A1 (en) 2022-02-15 2023-08-24 Takeda Vaccines, Inc. Dengue vaccine batch mixing process
WO2023215383A1 (en) 2022-05-04 2023-11-09 Takeda Vaccines, Inc. Computer-based determination of flavivirus infectivity

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002516824A (en) 1998-05-29 2002-06-11 エピミューン， インコーポレイテッド Identification of a Broadly Reactive DR-Restricted Epitope
JP2002540168A (en) * 1999-03-26 2002-11-26 ウォルター リード アーミー インスティテュート オブ リサーチ Multivalent dengue virus vaccine
US6537557B1 (en) 1999-03-26 2003-03-25 The United States Of America As Represented By The Secretary Of The Army Attenuated dengue-4 virus vaccine
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
US7094411B2 (en) * 2000-02-16 2006-08-22 The United States Of America As Represented By The Department Of Health And Human Services Avirulent, immunogenic flavivirus chimeras
EP1159969A1 (en) 2000-05-30 2001-12-05 Aventis Pasteur Composition vaccinale
EP1159968B1 (en) * 2000-05-30 2008-10-29 Mahidol University Attenuated strains of Dengue virus and their use in a vaccine composition
AU2003239932A1 (en) * 2002-05-31 2003-12-19 Acambis, Inc. Tetravalent dengue vaccines
AU2004236636B2 (en) * 2003-03-24 2010-02-04 The Scripps Research Institute DNA vaccines against tumor growth and methods of use thereof
ATE475706T1 (en) * 2005-06-17 2010-08-15 Sanofi Pasteur ATTENUATED DENGUE SEROTYPE 2 STRAIN
BRPI0613328A2 (en) * 2005-06-17 2011-01-04 Sanofi Pasteur live attenuated dengue-1 virus strain, immunogenic composition, vaccine composition, isolated nucleic acid, isolated polyprotein and polyprotein fragment
AU2006280144B2 (en) * 2005-08-10 2012-06-14 Sanofi Pasteur Biologics, Llc Vaccination against dengue virus infection
US7968102B2 (en) * 2006-01-13 2011-06-28 Sanofi Pasteur S.A. Dengue chimeric viruses
AR061197A1 (en) * 2006-06-07 2008-08-13 Sanofi Pasteur DENGUE VIRUS 3 CEPAS VIVAS ATENUADAS
FR2903605A1 (en) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa IMMUNIZATION METHOD AGAINST THE FOUR SEROTYPES OF DENGUE
FR2906724B1 (en) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa METHOD OF IMMUNIZATION AGAINST THE 4 SEROTYPES OF DENGUE.

Also Published As

Publication number Publication date
US20080131460A1 (en) 2008-06-05
IL198466A0 (en) 2011-08-01
IL230052A0 (en) 2014-01-30
JP5269803B2 (en) 2013-08-21
CN101541344A (en) 2009-09-23
FR2909286A1 (en) 2008-06-06
KR20090087890A (en) 2009-08-18
AU2007327367B2 (en) 2013-05-09
WO2008065315A1 (en) 2008-06-05
BRPI0718927A2 (en) 2014-04-08
TWI400249B (en) 2013-07-01
IL198466A (en) 2014-01-30
ZA200902540B (en) 2010-07-28
EP2099483A1 (en) 2009-09-16
TW200829599A (en) 2008-07-16
JP2010511022A (en) 2010-04-08
US20100239612A1 (en) 2010-09-23
US7718359B2 (en) 2010-05-18
MY180698A (en) 2020-12-07
EP2099483B1 (en) 2013-12-25
FR2909286B1 (en) 2012-06-08
AU2007327367A1 (en) 2008-06-05
AR064009A1 (en) 2009-03-04
CA2668570A1 (en) 2008-06-05

Similar Documents

Publication Publication Date Title
MX2009004223A (en) Immunization protocol against the 4 dengue serotypes.
MY169275A (en) Method of immunization against the four serotypes of dengue
MX2009003417A (en) Immunisation method against the 4 dengue serotypes.
PH12019500289A1 (en) Vaccines directed against a human enteroviruses
JP2010505801A5 (en)
WO2005116270A3 (en) Influenza virus vaccine composition and method of use
WO2007002470A3 (en) Inactivated chimeric vaccines and related methods of use
WO2007124479A3 (en) Avian influenza viruses, vaccines, compositions, formulations, and methods
JP2010511022A5 (en)
NO20070551L (en) Vaccine Compositions and Methods for Treating Coronavirus Infection.
UA99659C2 (en) Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof
WO2007057763A3 (en) Nitric oxide as an anti-viral agent, vaccine and vaccine adjuvant
MX2021002586A (en) Dengue vaccine unit dose and administration thereof.
WO2009060281A3 (en) Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties
MY184428A (en) Compositions and methods for administration of vaccines against dengue virus
TN2011000182A1 (en) Live, attentuated respiratory syncytial virus
JP2009514840A5 (en)
NZ591950A (en) Use of various antigens including antigens from mycoplasma bovis in multivalent vaccine composition
CA2915027A1 (en) Compositions and methods for administration of vaccines against dengue virus
MY153290A (en) Multivalent avian influenza vaccines
NO20090290L (en) Polyvalent vaccine against salmonid alphavirus infections
NO20075194L (en) vaccine
MXPA03009763A (en) Foot and mouth disease virus vaccine.
NZ583377A (en) Method of eliciting an immune response against pandemic influenza virus
NZ591738A (en) Non-typhoidal salmonella vaccines comprising a polypeptide which is an outer membrane protein d of non typoidal salmonella

Legal Events

Date Code Title Description
FG Grant or registration